Yes, the fight against these forces is difficult because

New Post Public Reply Private Reply Replies (5) Message Board
MGK_2
921
Yes, the fight against these forces is difficult because they have been there for a long time. They have become entrenched and they enjoy their habitation and don't want to give it up.
We are all about revolution, against all that tyranny. It is not all about them. It is not all about how they can make more with expensive bandaids. No. Now, the tide has turned. It is about Normalization. It is about proper operation. It is about self cure.
How do we propose the return back to baseline? The normal ratio, the normal balance, how are these achieved? Add Leronlimab. It all comes back to this new found mechanism of action that was discovered in the long haulers trial, where CCR5 numbers increased in patients who responded to LL when they had been decreased resulting from long bouts of covid sickness.
Remember the Tower of Babel. All the peoples of the Earth lived together and were growing in knowledge and power. They all spoke one language and took stones and made mortar and built a tower and then they were growing in power. God looked down and did not appreciate their growing might and wanted to put a stop to that. What did He do? He confounded their languages. Nobody spoke the same language anymore. Nobody could understand what the other was saying. That put an end to the tower and people found others who spoke like they did and went to different parts of the Earth to reside. God does not like "one ness". He likes to separate groups. He like the fact that there are multiple countries on Earth. He likes borders between them.
This sharing, or one world order, or one world religion is not in line with how He operates. Anyway, back to the analogy. How does Leronlimab play God? Well, nothing can bind to CCR5 better than LL. Not HIV, not even CCL5. Remember that CCR5 is a cytokine doing the communication at the heart of the Immunomodulatory Cascade of events which produce appropriate inflammatory response for a given stimulus of disease. Well, when everything is operating as it should, and everything is in balance and the ratios are correct, CCR5 is communicating with a bunch of other cytokines getting things done appropriately. Bacteria, virus', fungi, etc are getting killed. New found diseases are discovered and fought against. Memory is formed and maintained so when it is encountered again, the antibodies may quickly be manufactured. Those antibodies are helped to be manufactured. It's a conglomerate of an Army, working with a Navy, which works with an Air Force, a Space Force, who all work with Marines and Coast Guard. Everyone has their own special function and everyone does it well because CCR5 is in good quantity and free and available to communicate.
Now disease comes forth and spews CCL5 into the heart of the communication pathway of the immune system. Cancer, tumors exude CCL5 cytokine which strongly binds to CCR5 effectively jamming communication between all the militia. Available and free surface expression CCR5 dwindles. No communication and the militia begins working for the enemy, building a vascular blood supply for the tumors, deluding the T-regulatory cells to trick the natural killer cytotoxic T cells not to kill the tumor cells and to leave them alone and to allow them to freely pass through the arteries and veins to become circulating tumor cells and metastasize.
No, the object of the game is not to build a massive Tumor, nor is it to proliferate a cancer. The object is to keep a human being free from cancer. Free from fatty liver. Free from scarred liver.
When CCR5 communication is used in excess or the opposite, if there is a lack of use of CCR5, something is wrong. If it is used in excess, it has been hijacked in the way CCL5 Rantes jammed up the Internet/Interleukin signal. If there is a lack in communication, cells are so fatigued, they are unable to produce more CCR5.
People were not supposed to be talking the same language. There had to be various modes of thought and to allow that, God had to break it up. Someone was leading those people to build this gawky tower. Why the hell was it necessary? Because someone at the top had an idea and they had to comply. That was shut down. Leronlimab is added, it takes out the CCL5, and LL goes in its place. The difference is though, that LL does not shut down the communication for Adaptive Immunity. It allows CCR5 to continue to work and communicate for Adaptive Immunity. It does however shut down the communication for Innate Immunity, (built in which is more inflammatory). So, LL blocks off the jammer and there is nothing which binds to CCR5 with more affinity than LL and it has a half month of about a month.
Can you see now that LL has fixed the problem at its source. It confounds the enemy. It normalizes human immuno-physiology allowing our own immune systems to address every pathology it normally would provided its cellular communication channels, the internet/interleukin between the various flanks of militia remain robust and operational, free of jammed communication or black out periods. Even when there is a dearth of communication, Leronlimab induces the restoration and normalization of appropriate communication levels for the purpose of keeping the human body free and clear of disease. Leronlimab is harmless if given to a healthy individual and does not affect their capacity to fight disease. When given to a patient who has developed a disease caused by a faulty immune system, it restores proper communication between the troops so they may form the appropriate means to eradicate the foe. Anytime inflammation exists in the body, it is the job of the immune system to eradicate that.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viatris Declares Quarterly Dividend Amid Acquisition Buzz

Updated Category News Views 65

A Dividend Declaration with a Side of Mergers Viatris, the healthcare giant operating on a global scale, has been making some noise recently. On the surface, it's another quarterly dividend—$0.12 per share, set to hit the pockets of shareholders on December 16. But there's a lot more cooking under the hood of this announcement that ticks just about every box for a...

Continue Reading
Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

Updated Category News Views 110

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

Continue Reading
Greenberg Traurig's Stars Shine in Delaware's Legal Scene

Updated Category News Views 56

Five Lawyers, One Prestigious List Eating lunch today, I nearly dropped my sandwich when I read that five top-notch attorneys from Greenberg Traurig have snagged spots on Delaware Today's 2026 Top Lawyers List. This isn't your everyday pat on the back; it's Delaware, the heavyweight champ of corporate law, after all. The Legal Eagles of Greenberg Traurig Kicking off this...

Continue Reading
Samsung Ups Stake in TCL CSOT: A Game-Changer?

Updated Category News Views 137

Samsung Electronics' Strategic Play Sometimes it takes a gutsy move to shake up the industry, and Samsung Electronics just went for it. Snagging a 10.16% stake in TCL CSOT isn't just some run-of-the-mill acquisition. It's a calculated chess piece placement in the cutthroat display tech arena. Unpacking the Stake Game This latest move shifts Samsung Display's stake to...

Continue Reading
Black Friday Doubt Grows: Just 54% Trust Real Deals

Updated Category News Views 93

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

Continue Reading
LULU Under Fire: Class Action Opportunities Await

Updated Category News Views 138

Lululemon Faces a Legal Storm If you're holding shares in Lululemon (NASDAQ: LULU), you might want to sit up and pay attention. Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, is gathering folks for a securities fraud class action lawsuit against Lululemon. They're pointing fingers at the company for cooking the books – or at least not being...

Continue Reading
Askey & Icom Team Up: Trading Airwaves for Partnerships

Updated Category News Views 20

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Continue Reading
Sectra Powers Radiology at Mount Sinai with AI Integration

Updated Category News Views 97

AI and Radiology: A Match Made for Mount Sinai Today, we're diving into a technological leap that promises to shake up the healthcare sector—Sectra's integration of artificial intelligence with radiology at Mount Sinai Health System. The deal pairs Sectra's prowess in medical imaging IT and cybersecurity with the healthcare giant in New York, aiming to redefine how...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 32

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
Atlas-SSI Expands Grip in Water Control Space

Updated Category News Views 191

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...

Continue Reading

Top 5 Most Recently Viewed Articles

Medicenna Reveals Promising MDNA11 Results at SITC Meeting

Updated Category News Views 197

Medicenna's Groundbreaking MDNA11 Updates Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, recently made headlines at a prominent annual meeting dedicated to cancer research. Their innovative approach using MDNA11, a long-acting interleukin-2 super-agonist, is showing significant promise, particularly in the context of advanced solid tumors that have...

Continue Reading
Melco Resorts Restructures Operations for Future Growth

Updated Category News Views 267

Melco Resorts Announces Strategic Changes to Casino Operations Recent developments from Melco Resorts & Entertainment Limited (Nasdaq: MLCO) signal a significant shift in the company's operational strategy. The company, known for its luxurious integrated resort facilities across Asia and Europe, has made the difficult decision to cease operations at the Grand Dragon...

Continue Reading
Verizon Highlights Surge in Cyber Threats in Latest Report

Updated Category News Views 489

Insights from Verizon's 2025 Data Breach Investigations Report In a pivotal revelation, Verizon Business has issued its latest Data Breach Investigations Report, shedding light on an unsettling surge in system intrusions affecting organizations across the Asia-Pacific region. The report emphasizes that a staggering 80% of reported data breaches can be traced back to these...

Continue Reading
BrookBridge Wealth Transitions to LPL Private Wealth Management

Updated Category News Views 109

BrookBridge Private Wealth Joins LPL Financial BrookBridge Private Wealth has officially joined LPL Financial, a move designed to deepen client service and widen what the firm can offer. By aligning with LPL, the team can focus on high-net-worth clients while keeping the personalized, one-to-one approach that defines their work. The transition gives them room to tailor...

Continue Reading
Breckenridge Expands Product Line with Everolimus Approval

Updated Category News Views 225

Breckenridge Announces FDA Approval for Everolimus Tablets In an impressive stride towards enhancing healthcare accessibility, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, recently revealed the final FDA approval for Everolimus Tablets for Oral Suspension (TFOS). This generic medication, available in 2mg, 3mg, and 5mg doses, serves as a...

Continue Reading